Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas Civik
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 56
- Beta
- 1.34
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -14.00
Financials
Revenue
$0.00-100.0%Net Income
$-25.35MEBITDA
$-25.05MFree Cash Flow
$-18.21MEPS (diluted)
$-0.40Shares Outstanding (diluted)
63.99M+6826.1%Operating Expenses
$25.99MCash & Debt
$33.00MReturn of Capital
$0.00Revenue by Segment (annual)
$2.82MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $13.86M | $-79.62M | $-1.28 |
| 2024 | $16.15M | $-77.33M | $-1.32 |
| 2023 | $0.00 | $-73.79M | $-1.85 |
| 2022 | $0.00 | $-120.72M | $-3.57 |
| 2021 | $0.00 | $-75.97M | $-2.53 |
| 2020 | $0.00 | $-12.83M | $-0.37 |
| 2019 | $0.00 | $-2.77M | $-0.08 |
Valuation
PYXShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+200.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·23h ago·Neutral
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live webcast on September 9, 2026 at 7:30 a.m.
View source ↗ - Newsglobenewswire.com·1d ago·Neutral
…rship transition reflects continued focus on advancing MICVO through key clinical milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that its Board of Directors has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective as of September 4, 2026.
View source ↗ - Newsglobenewswire.com·8d ago·Neutral
Pyxis Oncology to Participate in Upcoming Investor Conferences BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in fireside chats at three upcoming conferences.
View source ↗
Earnings
Mon, Nov 2(in 8 weeks)
Consensus estimate $-0.27 per share
Typical surprise -5.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.40 vs $-0.35miss
- Thu, May 14$-0.37 vs $-0.35miss
- Mon, Mar 23$-0.29 vs $-0.35beat
- Mon, Nov 3$-0.35 vs $-0.36beat
- Thu, Aug 14$-0.30 vs $-0.36beat
- Thu, May 15$-0.35 vs $-0.29miss
Estimates and results for PYXS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PYXS officers and directors.
- Bought
- $5.2m
- Sold
- $204k
10 trades
9 trades
- Dupont Jakobsold
- Humphrey Rachelsold
- Humphrey Rachelsold
- Humphrey Rachelsold
- Connealy Pamela Annbought
- Connealy Pamela Annbought
- Connealy Pamela Annbought
- Wadhane Jitendrabought
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.